LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial
Titel:
LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial
Auteur:
Graeser, M. Gluz, O. Biehl, C. Ulbrich-Gebauer, D. Palatty, J. Christgen, M. Kuemmel, S. Grischke, E-M. Augustin, D. Braun, M. Potenberg, J. Wuerstlein, R. Eulenburg, C. Kates, R. Kolberg-Liedtke, C. Feuerhake, F. Kreipe, H. Nitz, U. Harbeck, N.